JWM
VNDA icon

JPL Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

JPL Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380 Buy
62
+35
+130% +$229 ﹤0.01% 1433
2026
Q1 		$187 Buy
+27
New +$208 ﹤0.01% 1420

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JPL Wealth Management's VNDA Position: Q2 2026 in Review

JPL Wealth Management increased its Vanda Pharmaceuticals (VNDA) stake by 130% in Q2 2026, buying an estimated $229 and bringing the position to 62 shares worth $380. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

JPL Wealth Management first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • JPL Wealth Management held 62 shares of Vanda Pharmaceuticals worth $380 as of Q2 2026.
  • JPL Wealth Management bought 35 Vanda Pharmaceuticals shares in Q2 2026, an estimated $229.
  • Vanda Pharmaceuticals made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #1433 holding.
  • JPL Wealth Management first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.